Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association

Post time 7 day(s) ago

journal：Diabetes Care

Authors：Kenneth Cusi; Manal F. Abdelmalek; Caroline M. Apovian; Kirthikaa Balapattabi; Raveendhara R. Bannuru; Diana Barb; Joan K. Bardsley; Elizabeth A. Beverly; Karen D. Corbin; Nuha A. ElSayed; Scott Isaacs; Fasiha Kanwal; Elizabeth J. Pekas; Caroline R. Richardson; Michael Roden; Arun J. Sanyal; Jay H. Shubrook; Zobair M. Younossi; Mandeep Bajaj

Published date：2025-7-1

DOI：10.2337/dci24-0094

PDF link：https://diabetesjournals.org/car ... 11055/dci240094.pdf

Article link：https://doi.org/10.2337/dci24-0094

Article Source：American Diabetes Association。

Remark：

Post time 7 day(s) ago

: This post has been completed
Completed attachments will be deleted within 24 hours.

[Other] Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association

Best Answer

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Other] Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association Copy